Skip to main content
SpringerLink
Log in

Antithrombotics in Tumor Growth and Metastasis

  • Chapter
Bone Metastasis

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 706 Accesses

Abstract

Metastasis of cancer cells from a primary site involves a sequence of events, including the extravasation of the tumor cells into circulation and the interactions with platelets and other components of the hemostatic system (1,2). These interactions, in turn, result in the adhesion and penetration of these metastatic cells and subsequent intravasation into the tissue. Several studies demonstrated that tumor cells form complexes with platelets, fibrin, and leukocytes in the vasculature, forming microemboli (3,4). Thrombin is a key final common pathway that plays a significant role in activating platelets and generating fibrin for enhanced tumor metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Haemost 2002; 28:45–52.

    Article  CAS  Google Scholar 

  2. Mousa SA, Fareed JW. Advances in anticoagulant, antithrombotic and thrombolytic drugs. Exp Opin Invest Drugs 2001; 10:157–162.

    Article  CAS  Google Scholar 

  3. Chambers AF. The metastatic process: basic research and clinical implications. Oncol Res 1999; 11:161–168.

    PubMed  CAS  Google Scholar 

  4. Chambers AF, MacDonald IC, Schmidt EE, Koop S, Morris VL, Khokha R, et al.. Steps in tumor metastasis: new concepts from intra-vital video microscopy. Cancer Metastasis Rev 1995; 14:279–301.

    Article  PubMed  CAS  Google Scholar 

  5. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. PNAS 2001; 98: 3352–3357.

    Article  PubMed  CAS  Google Scholar 

  6. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. Differential interactions of heparin and heparin sulfate glycosaminoglycans with the selectins. J Clin Invest 1998; 101:877–889.

    PubMed  CAS  Google Scholar 

  7. Varki A, Varki NM. P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications. Braz J Med Biol Res 2001; 34:711–717.

    Article  PubMed  CAS  Google Scholar 

  8. Trousseau A. Phlegmasia alba dolens. Clinique medicale de l’hotel-dieu de Paris. London: New Sydenham Society, 1865:3:94.

    Google Scholar 

  9. Schiller H, Bartscht T, Arlt A, Zahn MO, Seifert A, Bruhn T, Bruhn HD, et al. Thrombin as a survival factor for cancer cells: thrombin activation in malignant effusions in vivo and inhibition of idarubicininduced cell death in vitro. Int J Clin Pharmacol Ther 2002; 40(8):329–335.

    PubMed  CAS  Google Scholar 

  10. Sorensen H, Mellemkjaer L, Olsen J, Baron J. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343:1846–1850.

    Article  PubMed  CAS  Google Scholar 

  11. Caine GJ, Lip GY. Anticoagulants as anticancer agents? Lancet Oncol 2002; 3(10):591,592.

    Article  Google Scholar 

  12. Lebeau B, Chastang C, Brechot J-M, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 1994; 74:38–45.

    Article  PubMed  CAS  Google Scholar 

  13. Chahinian A, Propert K, Ware J, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989; 7: 993–1002.

    PubMed  CAS  Google Scholar 

  14. Thornes R. Coumarins, melanoma and cellular immunity. In: McBrien D, Slator T, eds. Protective Agents in Cancer. London: Academic Press, 1983:43–56.

    Google Scholar 

  15. Pintucci G, Froum S, Pinnell J, Mignatti P, Rafii S, Green D. Trophic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). Thromb Haemost 2002; 88(5):834–842.

    PubMed  Google Scholar 

  16. Manegold PC, Hutter J, Pahernik SA, Messmer K, Dellian M. Platelet-endothelial interaction in tumor angiogenesis and microcirculation. Blood 2003; 101(5):1970–1976

    Article  PubMed  CAS  Google Scholar 

  17. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002; 62(5): 343–350.

    Article  PubMed  CAS  Google Scholar 

  18. Verheul HM, Pinedo HM. Tumor growth: a putative role for platelets? Oncologist 1998; 3(2):II.

    Google Scholar 

  19. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3(12 Pt 1):2187–2190.

    PubMed  CAS  Google Scholar 

  20. Amirkhosravi A, Amaya M, Desai H, Francis JL. Platelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity. Blood Coagul Fibrinolysis 2002; 13(6): 505–512.

    Article  PubMed  CAS  Google Scholar 

  21. Gasic GJ, Gasic TB, Stewart CC. Anti-metastatic effect associated with platelet reduction. Pathology 1998; 61:46–52.

    Google Scholar 

  22. Amirkhosravi A, Mousa SA, Amaya M, Blaydes S, Desai H, Meyer T, et al. Inhibition of tumor cellinduced platelet aggregation and lung metastasis by the oral GPIIb/IIIa antagonist XV454. Thromb Haemost 2003; 90(3):549–554.

    PubMed  CAS  Google Scholar 

  23. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada MT. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002; 62(10): 2824–2833.

    PubMed  CAS  Google Scholar 

  24. Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost 2002; 28(1): 53–66.

    Article  PubMed  CAS  Google Scholar 

  25. Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003; 39(2):184–191.

    Article  PubMed  CAS  Google Scholar 

  26. Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci 2003; 100(24):14,205–14,210.

    Article  PubMed  CAS  Google Scholar 

  27. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 1998; 351:1077–1080.

    Article  PubMed  CAS  Google Scholar 

  28. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1982; 62:14–31.

    Google Scholar 

  29. Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997; 78:133–136.

    PubMed  CAS  Google Scholar 

  30. Falanga A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis 1998; 28:50–60.

    Article  CAS  PubMed  Google Scholar 

  31. Kakkar AJ, De Ruvo N, Tebbutt S, Williamson RCN. Extrinsic pathway activation with elevated tissue factor and factor VIIa in patients with cancer. Lancet 1995; 346:1004,1005.

    Article  Google Scholar 

  32. Staton CA, Brown NJ, Lewis CE. The role of fibrinogen and related fragments in tumor angiogenesis and metastasis. Exp Opin Biol Ther 2003; 3(7):1105–1120.

    Article  CAS  Google Scholar 

  33. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334:682–687.

    Article  PubMed  CAS  Google Scholar 

  34. Kakkar AJ, Williamson RC. Prevention of venous thromboembolism in cancer using low molecular weight heparin. Haemostasis 1997; 27(Suppl 1):32–37.

    PubMed  CAS  Google Scholar 

  35. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998; 80:10–23.

    PubMed  CAS  Google Scholar 

  36. von Tempelhoff GF, Harenberg J, Neimann F, et al. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int Oncol 2000; 16:815–824.

    Google Scholar 

  37. Zacharski LR. Anticoagulant in cancer treatment: malignancy as a solid phase coagulopathy. Cancer Lett 2002; 186:1–9.

    Article  PubMed  CAS  Google Scholar 

  38. Meyers G, Marjanovic Z, Valcke J, et al. Comparison of LMWH and wafarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 2002; 162:1729–1735.

    Article  Google Scholar 

  39. Trousseau A. Plegmasia alba dolens. In: Baillier JB, ed. Clinique de l’Hotel-Dieu de Paris, 2nd ed. 1865:3:654–712.

    Google Scholar 

  40. Howard W. Phlebitis and thrombosis. Lancet 1906; 1:650–655.

    Google Scholar 

  41. Dvorak HF. Thrombosis and cancer. Human Pathol 1987; 18:275–284.

    Article  CAS  Google Scholar 

  42. Kakkar AK, Levine MN, Prandoni P, Lee AY, Rasmussen MS, Kuter D. What is the role for antithrombotics in cancer care? Interactive session with panel discussion. Cancer Treat Rev 2002; 28(3): 157–159.

    Article  PubMed  Google Scholar 

  43. Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1983; 2:41–73.

    Article  PubMed  CAS  Google Scholar 

  44. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79(1):1–17.

    PubMed  CAS  Google Scholar 

  45. Nielsen JI, Ostergaard P. Chemistry of heparin and low molecular weight heparin. Acta Chir Scand Suppl 1988; 543:52–56.

    PubMed  CAS  Google Scholar 

  46. Engelberg H. Actions of heparin that may affect the malignant process. Cancer 1999; 85: 257–272.

    Article  PubMed  CAS  Google Scholar 

  47. Linhardt RJ and Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Haemost 1999; 25(3):5–16.

    CAS  Google Scholar 

  48. Mousa SA, Bozarth J, Larnkjaer A, Johanson K. Vascular effects of heparin molecular weight fractions and LMWH on the release of TFPI from human endothelial cells. Blood 2000; 16(11):59.

    Google Scholar 

  49. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975–982.

    Article  PubMed  CAS  Google Scholar 

  50. Levine M, Hirsh J, Gent M, et al. Double-blind randomized trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343:886–889.

    Article  PubMed  CAS  Google Scholar 

  51. Mousa SA. Mechanisms of angiogenesis in vascular disorders: potential therapeutic targets. In: Mousa SA, ed. Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications. Gorgtown, TX: Landes, 2000.

    Google Scholar 

  52. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25(2):173–182.

    PubMed  CAS  Google Scholar 

  53. Markus G. The role of haemostasis and fibrinolysis in the metastatic spread of cancer. Thromb Hemost 1984; 10:61–72.

    Article  CAS  Google Scholar 

  54. Ruf W, Mueller BM. Tissue factor in cancer angiogenesis and metastasis. Cur Opin Haematol 1996; 3:379–384.

    Article  CAS  Google Scholar 

  55. Paredes N, Xu L, Berry LR, Chan AK. The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces. Br J Haematol 2003; 120(2):315–324.

    Article  PubMed  CAS  Google Scholar 

  56. Pinedo H, Verheul H, D’Amato R, Folkman J. Involvement of platelets in tumor angiogenesis? Lancet 1998; 352:1775–1777.

    Article  PubMed  CAS  Google Scholar 

  57. Wojtukiewicz M, Zacharski L, Memoli V, et al. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 1990; 10:579–582.

    PubMed  CAS  Google Scholar 

  58. Zacharski L, Wojtukiewicz M, Costantini V, et al. Pathways of coagulation/fibrinolysis activation in malignancy. Sem Thromb Hemostas 1992; 18:104–116.

    CAS  Google Scholar 

  59. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and anti-angiogenic properties of tumor cells in mice. J Clin Invest 1994; 94:1320–1327.

    Article  PubMed  CAS  Google Scholar 

  60. Engelberg H. Actions of heparin in the atherosclerotic process. Pharmacol Rev 1996; 48: 327–352.

    PubMed  CAS  Google Scholar 

  61. Nelson RM, Ceccioni D, Roberts WG, et al. Heparin oligosaccharides bind L-and P-selectins and inhibit acute inflammation. Blood 1993; 82:3253–3258.

    PubMed  CAS  Google Scholar 

  62. Mousa SA, Mohamed S. Anti-angiogenic mechanisms and efficacy of the low-molecular-weight heparin: anti-cancer efficacy. Oncol Rep 2004; 12:683–688.

    PubMed  CAS  Google Scholar 

  63. Amirkhosravi A, Mousa SA, Amaya M, Francis JL. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 2003; 1(9):1972–1976.

    Article  PubMed  CAS  Google Scholar 

  64. Mousa, SA. Anticoagulants in thrombosis and cancer: the missing link. Exp Rev Anticancer Ther 2002; 2(2):227–233.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Basic and Pharmaceutical Sciences, Albany College of Pharmacy & Pharmaceutical Research Institute, Albany, NY

    Shaker A. Mousa PhD, MBA, FACC, FACB

Authors
  1. Shaker A. Mousa PhD, MBA, FACC, FACB
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology and Molecular Medicine/Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada

    Gurmit Singh PhD

  2. Calcium Research Laboratory, McGill University Health Centre, Montreal, Quebec, Canada

    Shafaat A. Rabbani MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Mousa, S.A. (2005). Antithrombotics in Tumor Growth and Metastasis. In: Singh, G., Rabbani, S.A. (eds) Bone Metastasis. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1385/1-59259-892-7:177

Download citation

  • DOI: https://doi.org/10.1385/1-59259-892-7:177

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-403-6

  • Online ISBN: 978-1-59259-892-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation